Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Peptide Antibiotics Market Forecast: What Value Will The Market Reach By 2030?
The peptide antibiotics market size has experienced robust growth in recent years. This market is set to expand from $5.77 billion in 2025 to $6.32 billion in 2026, progressing at a compound annual growth rate (CAGR) of 9.6%. The historical growth of this market is attributable to several factors, including the increasing prevalence of antibiotic-resistant bacterial strains, higher rates of hospital-acquired infections, developments in peptide synthesis technologies, expanding clinical research focused on infectious diseases, and government initiatives funding antibiotic R&D.
The peptide antibiotics market is anticipated to experience substantial growth over the next few years. It is projected to expand to $9.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period is attributable to factors such as the increasing prevalence of multi-drug resistant infections, the global expansion of healthcare infrastructure, technological improvements in peptide delivery systems, growing collaborations with CDMOs, and the rising awareness and adoption of precision medicine approaches. Significant trends during this period include an escalating demand for multi-drug resistant (MDR) infection solutions, the expanded use of peptide antibiotics for hospital-acquired infections, an increase in contract manufacturing and CDMO partnerships, the greater adoption of personalized and targeted antibiotic therapies, and a focus on developing peptide antibiotics with reduced toxicity and side effects.
Get A Free Sample Report With In-Depth Market Insights:
Peptide Antibiotics Market Growth Catalysts And Demand Drivers
The peptide antibiotics market is anticipated to expand due to the growing occurrence of various infectious diseases, which are conditions caused by harmful microbes like bacteria, fungi, and parasites. Factors such as rapid urbanization, climate change, and the heightened risk of new diseases contribute significantly to this rise, boosting the demand for peptide antibiotics that work by physically disrupting cell membranes to exert their antibacterial effects. For example, the World Health Organization reported in May 2024 that dengue cases in the America region exceeded seven million by April 2024, a notable increase from 4.6 million reported throughout 2023. Consequently, the rising incidence of infectious diseases is a key driver for the peptide antibiotics market. The peptide antibiotics market is also projected to grow due to a rise in chronic diseases, defined as conditions lasting a year or more, requiring continuous medical care, and impacting daily life. The escalation of these diseases is linked to factors such as higher tobacco use, inadequate nutrition, lack of physical activity, and excessive alcohol intake. Peptide antibiotics are utilized in chronic disease treatment through targeted drug delivery. For instance, the World Health Organization reported in February 2024 that new cancer cases are expected to exceed 35 million by 2050, marking a 77% surge from the approximately 20 million cases estimated in 2022. Thus, the expanding prevalence of chronic conditions is accelerating the peptide antibiotics market’s growth.
Peptide Antibiotics Market Segment Landscape: Which Areas Lead Development?
The peptide antibiotics market covered in this report is segmented –
1) By Type: Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics
2) By Drugs: Daptomycin, Dalbavancin, Telavancin, Other Drugs
3) By Disease Outlook: Skin Infection, HABP Or VABP, Blood Stream Infection, Other Diseases
4) By Distribution Channel: Hospitals, Homecare, Specialty Clinics, Other Distribution Channels
Subsegments:
1) By Ribosomal Synthesized Peptide Antibiotics: Aminoglycosides, Macrolides, Tetracyclines, Lincosamides
2) By Non-Ribosomal Synthesized Peptide Antibiotics: Bacitracins, Vancomycin, Polymyxins, Cyclic Lipopeptides
Peptide Antibiotics Market Trends Shaping Long-Term Demand
Leading companies operating within the peptide antibiotics market are introducing generic versions, thereby providing a more affordable alternative for patients. These generic peptide antibiotics serve as cost-effective, off-patent replacements for brand-name peptide-based antibiotics, which are used to address various bacterial infections. For instance, in July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its product line with the launch of a generic version of Daptomycin for Injection. Daptomycin for Injection is a type of peptide antibiotic, specifically a cyclic lipopeptide antibiotic produced by non-ribosomal machinery. This generic version is accessible in both 350 mg and 500 mg strengths and is prescribed for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients and pediatric patients aged 1 to 17 years.
Peptide Antibiotics Market Industry Leaders And Competitive Landscape
Major companies operating in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd.
View The Full Peptide Antibiotics Market Report:
Peptide Antibiotics Market Geographic Distribution And Regional Opportunities
North America was the largest region in the peptide antibiotics market in 2025. The regions covered in the peptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model